Why Semaglutide is an inflection point for India’s generics sector?
More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies about 20% of the world’s generic medicines by volume. With the expiry of Novo Nordisk’s primary patent in India this March, Semaglutide — the active ingredient…
Read More “Why Semaglutide is an inflection point for India’s generics sector?” »